FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2002055332> ?p ?o ?g. }

• W2002055332 endingPage "432" @default.
• W2002055332 startingPage "428" @default.
• W2002055332 abstract "Background Cabazitaxel and AA have been approved by the US Food and Drug Administration for use after docetaxel in mCRPC. Recently, CAB appeared to be active when given after AA. AA is capable of inducing AR splice variants that confer ligand-independent AR transactivation. Because microtubule-targeting agents impair AR nuclear transport and activity, we raised concerns about CAB efficacy after AA failure in mCRPC. Patients and Methods One hundred thirty mCRPC patients received AA after docetaxel treatment in compassionate programs. Of them, 24 (18.4%) subsequently received CAB. We retrospectively reviewed their data using conventional methods. Results Twenty-four patients received a median of 4 (range, 1-13) CAB cycles. Nineteen (79.1%) of them received primary prophylaxis with growth factors. Median patient characteristics were: age 65 (range, 57-85) years; Gleason score: 8 (range, 6-10); and PSA: 128.1 (range, 0.01-1700) ng/mL. A PSA response (≥ 50% decrease from baseline) occurred in 6 (31.5%) of 19 evaluable patients (95% confidence interval [CI], 11.8-54.2%). CAB therapy obtained a partial response in 2 of the 13 (15.3%) evaluable patients (95% CI, 2.9-45.4%). Median survival from initiation of CAB was 8.2 (95% CI, 3.34-13.05) months, from AA 16.1 (95% CI, 11.56-20.64) and from docetaxel 32.0 (95% CI, 11.56-39.69). Conclusion A limited number of patients with mCRPC received CAB after docetaxel and AA treatment. In this selected population, CAB was active." @default.
• W2002055332 created "2016-06-24" @default.
• W2002055332 creator A5000987473 @default.
• W2002055332 creator A5009846091 @default.
• W2002055332 creator A5020715864 @default.
• W2002055332 creator A5021072697 @default.
• W2002055332 creator A5024357764 @default.
• W2002055332 creator A5026854648 @default.
• W2002055332 creator A5027326315 @default.
• W2002055332 creator A5029994127 @default.
• W2002055332 creator A5049181473 @default.
• W2002055332 creator A5052653659 @default.
• W2002055332 creator A5062199973 @default.
• W2002055332 creator A5066728112 @default.
• W2002055332 creator A5089230523 @default.
• W2002055332 date "2014-12-01" @default.
• W2002055332 modified "2023-10-16" @default.
• W2002055332 title "Activity of Cabazitaxel After Docetaxel and Abiraterone Acetate Therapy in Patients With Castration-Resistant Prostate Cancer" @default.
• W2002055332 cites W2019607817 @default.
• W2002055332 cites W2020031575 @default.
• W2002055332 cites W2054281770 @default.
• W2002055332 cites W2057400303 @default.
• W2002055332 cites W2072037375 @default.
• W2002055332 cites W2080134152 @default.
• W2002055332 cites W2101496134 @default.
• W2002055332 cites W2104127658 @default.
• W2002055332 cites W2108679313 @default.
• W2002055332 cites W2110534364 @default.
• W2002055332 cites W2123526148 @default.
• W2002055332 cites W2137467802 @default.
• W2002055332 cites W2148643283 @default.
• W2002055332 cites W2157980218 @default.
• W2002055332 cites W2164884291 @default.
• W2002055332 cites W2167331614 @default.
• W2002055332 cites W2170668585 @default.
• W2002055332 doi "https://doi.org/10.1016/j.clgc.2014.06.007" @default.
• W2002055332 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25066221" @default.
• W2002055332 hasPublicationYear "2014" @default.
• W2002055332 type Work @default.
• W2002055332 sameAs 2002055332 @default.
• W2002055332 citedByCount "30" @default.
• W2002055332 countsByYear W20020553322015 @default.
• W2002055332 countsByYear W20020553322016 @default.
• W2002055332 countsByYear W20020553322017 @default.
• W2002055332 countsByYear W20020553322019 @default.
• W2002055332 countsByYear W20020553322020 @default.
• W2002055332 countsByYear W20020553322022 @default.
• W2002055332 crossrefType "journal-article" @default.
• W2002055332 hasAuthorship W2002055332A5000987473 @default.
• W2002055332 hasAuthorship W2002055332A5009846091 @default.
• W2002055332 hasAuthorship W2002055332A5020715864 @default.
• W2002055332 hasAuthorship W2002055332A5021072697 @default.
• W2002055332 hasAuthorship W2002055332A5024357764 @default.
• W2002055332 hasAuthorship W2002055332A5026854648 @default.
• W2002055332 hasAuthorship W2002055332A5027326315 @default.
• W2002055332 hasAuthorship W2002055332A5029994127 @default.
• W2002055332 hasAuthorship W2002055332A5049181473 @default.
• W2002055332 hasAuthorship W2002055332A5052653659 @default.
• W2002055332 hasAuthorship W2002055332A5062199973 @default.
• W2002055332 hasAuthorship W2002055332A5066728112 @default.
• W2002055332 hasAuthorship W2002055332A5089230523 @default.
• W2002055332 hasConcept C119060515 @default.
• W2002055332 hasConcept C121608353 @default.
• W2002055332 hasConcept C126322002 @default.
• W2002055332 hasConcept C126894567 @default.
• W2002055332 hasConcept C143998085 @default.
• W2002055332 hasConcept C2775832370 @default.
• W2002055332 hasConcept C2777511904 @default.
• W2002055332 hasConcept C2777899217 @default.
• W2002055332 hasConcept C2778971682 @default.
• W2002055332 hasConcept C2780192828 @default.
• W2002055332 hasConcept C2781190966 @default.
• W2002055332 hasConcept C2908647359 @default.
• W2002055332 hasConcept C44249647 @default.
• W2002055332 hasConcept C530470458 @default.
• W2002055332 hasConcept C71924100 @default.
• W2002055332 hasConcept C90924648 @default.
• W2002055332 hasConcept C99454951 @default.
• W2002055332 hasConceptScore W2002055332C119060515 @default.
• W2002055332 hasConceptScore W2002055332C121608353 @default.
• W2002055332 hasConceptScore W2002055332C126322002 @default.
• W2002055332 hasConceptScore W2002055332C126894567 @default.
• W2002055332 hasConceptScore W2002055332C143998085 @default.
• W2002055332 hasConceptScore W2002055332C2775832370 @default.
• W2002055332 hasConceptScore W2002055332C2777511904 @default.
• W2002055332 hasConceptScore W2002055332C2777899217 @default.
• W2002055332 hasConceptScore W2002055332C2778971682 @default.
• W2002055332 hasConceptScore W2002055332C2780192828 @default.
• W2002055332 hasConceptScore W2002055332C2781190966 @default.
• W2002055332 hasConceptScore W2002055332C2908647359 @default.
• W2002055332 hasConceptScore W2002055332C44249647 @default.
• W2002055332 hasConceptScore W2002055332C530470458 @default.
• W2002055332 hasConceptScore W2002055332C71924100 @default.
• W2002055332 hasConceptScore W2002055332C90924648 @default.
• W2002055332 hasConceptScore W2002055332C99454951 @default.
• W2002055332 hasIssue "6" @default.
• W2002055332 hasLocation W20020553321 @default.
• W2002055332 hasLocation W20020553322 @default.

• next